Insulin glulisine is a rapidly acting analogue with a pharmacokinetic profile that is similar to those of insulin lispro and insulin aspart. [48] It is created by substituting lysine for ...

Three short acting insulins Lispro, Aspart and Glulisine will be investigated. Blood and urine samples will be collected from 1 week before administration, until 3 days after administration. The ...

It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). To our knowledge, this is one of the first reports of lipoatrophy ...

The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported in several studies. BIAsp 30 has been shown to be more effective in ...